Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/65725
Title: | Amitriptyline reconsidered : the relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes |
Authors: | Mifsud Buhagiar, Luana Serracino-Inglott, Anthony Azzopardi, Lilian M. LaFerla, Godfrey |
Keywords: | Psychotropic drugs -- Administration Pain -- Treatment Central pain Psychotropic drugs -- Side effects |
Issue Date: | 2020 |
Publisher: | University of Malta. Department of Pharmacy |
Citation: | Mifsud Buhagiar, L., Serracino-Inglott, A., Azzopardi, L. M., & LaFerla, G. (2020). Amitriptyline reconsidered : the relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes. American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition. |
Abstract: | Tricyclic antidepressants have played leading roles in psychiatric pharmacotherapy, with amitriptyline credited in the management of depression, and later also in neuropathic pain. It is accepted clinical practice to initiate therapy at a low dose, adjusting gradually to support tolerability. Exposure to amitriptyline and its metabolites is influenced by genetic polymorphisms of the cytochrome P450 subfamily enzymes1 , particularly CYP2C19 and CYP2D6. Evaluating the interplay between adverse outcomes and serum concentrations, as may be moderated by the dosage regimen and genotype-inferred variability on individual pharmacokinetics, should enable better informed use of this established drug |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/65725 |
Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Amitriptyline reconsidered The relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes.pdf | 694.46 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.